Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of ($1.01), $1.44 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $219.1 million versus the consensus estimate of $205.63 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.